Blandt de 110 patienter randomiseret til arm 3 (5- FU/ FA + Avastin) inden lukning af denne arm, var den mediane samlede overlevelse 18, 3 måneder og den mediane progressionsfri overlevelse var 8, 8 måneder.
Among the 110 patients randomised to Arm 3 (5-FU/ FA + Avastin) prior to discontinuation of this arm, the median overall survival was 18.3 months and the median progression free survival was 8.8 months.